NCT05275738: TGNT

The Glaucoma Nicotinamide Trial

Recruiting now NA Last updated 27 July 2023

What this trial tests

NA trial testing Nicotinamide in Glaucoma in 660 participants. Currently enrolling.

Timeline

18 May 2022

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	Umeå University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	660
Start date	18 May 2022
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	2 locations across Sweden

Drugs / interventions tested

• Nicotinamide (Nicotinamide) — full drug profile →
• Placebo

Conditions studied

• Glaucoma — all drugs for Glaucoma →

Sponsor

Umeå University

Who can join

18 and older, any sex, with Glaucoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Glaucoma Nicotinamide Trial (TGNT) is a prospective, randomized, placebo-controlled double-masked clinical trial composed of two cohorts; The Swedish Glaucoma Nicotinamide Trial (SGNT) and the Vitamin B3 In Glaucoma Study (VBIGS). Patients with open-angle glaucoma (OAG) will be randomized to receive either Nicotinamide or placebo through block randomization stratified by glaucoma subtype with a 1:1 allocation.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Peripheral blood mononuclear cell respiratory function is associated with progressive glaucomatous vision loss.
   Petriti B, Rabiolo A, Chau KY, Williams PA, et al · · 2024 · cited 29× · PMID 38886621 · DOI 10.1038/s41591-024-03068-6
2. Neuroprotection in Glaucoma: Basic Aspects and Clinical Relevance.
   Kuo CY, Liu CJ. · · 2022 · cited 20× · PMID 36579616 · DOI 10.3390/jpm12111884
3. Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies.
   Wang LH, Huang CH, Lin IC. · · 2024 · cited 15× · PMID 39458902 · DOI 10.3390/ph17101261
4. Oral nicotinamide provides robust, dose-dependent structural and metabolic neuroprotection of retinal ganglion cells in experimental glaucoma.
   Cimaglia G, Tribble JR, Votruba M, Williams PA, et al · · 2024 · cited 15× · PMID 39180087 · DOI 10.1186/s40478-024-01850-8
5. Nicotinamide: Bright Potential in Glaucoma Management.
   Babighian S, Gattazzo I, Zanella MS, Galan A, et al · · 2024 · cited 10× · PMID 39200120 · DOI 10.3390/biomedicines12081655
6. Nicotinamide Prevents Retinal Vascular Dropout in a Rat Model of Ocular Hypertension and Supports Ocular Blood Supply in Glaucoma Patients.
   Gustavsson ST, Enz TJ, Tribble JR, Nilsson M, et al · · 2023 · cited 9× · PMID 38010699 · DOI 10.1167/iovs.64.14.34
7. Challenging glaucoma with emerging therapies: an overview of advancements against the silent thief of sight.
   Sarkis S, Chamard C, Johansen B, Daien V, et al · · 2025 · cited 5× · PMID 40206485 · DOI 10.3389/fmed.2025.1527319
8. Update on Nicotinamide and Its Application in the Management of Glaucoma.
   Chiu TH, Hung SH, Lan CH, Yen WT, et al · · 2025 · cited 2× · PMID 41226823 · DOI 10.3390/ijms262110789